Clinical Development of PARP Inhibitors in Treating Metastatic Castration-Resistant Prostate Cancer

被引:39
|
作者
Adashek, Jacob J. [1 ]
Jain, Rohit K. [2 ]
Zhang, Jingsong [2 ]
机构
[1] Univ S Florida, H Lee Moffitt Canc Ctr & Res Inst, Dept Internal Med, Tampa, FL 33612 USA
[2] H Lee Moffitt Canc Ctr & Res Inst, Dept Genitourinary Oncol, 12902 USF Magnolia Dr, Tampa, FL 33612 USA
关键词
PARP inhibitors; DNA damage repair deficiency; prostate cancer; targeted therapy; DNA-REPAIR; POLY(ADP-RIBOSE) POLYMERASE; MAINTENANCE THERAPY; OVARIAN-CANCER; MUTANT-CELLS; OLAPARIB; NIRAPARIB; DEFECTS; TUMORS; BRCA2;
D O I
10.3390/cells8080860
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
The approval of upfront abiraterone for castration-sensitive prostate cancer and the approval of enzalutamide and apalutamide for non-metastatic castration-resistant prostate cancer have led to early utilization of potent androgen receptor (AR) signaling inhibitors in treating advanced prostate cancer. There is an unmet need to develop novel therapies beyond targeting AR signaling for metastatic castration-resistant prostate cancer (mCRPC). Poly (ADP-ribose) polymerase inhibitors (PARPi) belong to a class of targeted agents being developed for the treatment of homologous recombination repair (HRR) deficient tumors. Olaparib, rucaparib, niraparib, veliparib, and talazoparib were evaluated in early phase trials as a monotherapy for HRR-deficient mCRPC. Among them, olaparib and rucaparib have breakthrough designations for BRCA1/2-mutated mCRPC. Phase II studies also reported clinical activity of the PARPi and abiraterone combination and the PARPi checkpoint inhibitor combination in HRR-intact mCRPC. Ongoing phase III trials are testing these combinations as frontline or later line treatments for mCRPC. This review summarizes the critical clinical data as well as ongoing clinical trials for developing PARPi in treating mCRPC.
引用
收藏
页数:12
相关论文
共 50 条
  • [1] Therapeutic Potential of PARP Inhibitors in the Treatment of Metastatic Castration-Resistant Prostate Cancer
    Jang, Albert
    Sartor, Oliver
    Barata, Pedro C.
    Paller, Channing J.
    CANCERS, 2020, 12 (11) : 1 - 14
  • [2] Treatment of Metastatic Castration-resistant Prostate Cancer: Are PARP Inhibitors Shifting the Paradigm?
    Fujimoto, Naohiro
    Harada, Kenichi
    Shiota, Masaki
    Tomisaki, Ikko
    Minato, Akinori
    Nagata, Yujiro
    Kimuro, Rieko
    Harada, Mirii
    Fujisawa, Masato
    ANTICANCER RESEARCH, 2021, 41 (10) : 4687 - 4695
  • [3] PARP inhibitors and metastatic castration-resistant prostate cancer: uture directions and pitfalls
    Franza, A.
    Claps, M.
    Procopio, G.
    TRANSLATIONAL ONCOLOGY, 2022, 15 (01):
  • [4] PARP Inhibitors in Metastatic Castration-Resistant Prostate Cancer: Unraveling the Therapeutic Landscape
    Al-Akhras, Ashaar
    Chehade, Chadi Hage
    Narang, Arshit
    Swami, Umang
    LIFE-BASEL, 2024, 14 (02):
  • [5] The growing role of PARP inhibitors in the treatment of metastatic castration-resistant prostate cancer
    Panzone, John
    Rood, Gavrielle J.
    Goldberg, Hanan
    TRANSLATIONAL CANCER RESEARCH, 2023, 12 (12) : 3233 - 3240
  • [6] Combination of PARP Inhibitors and Androgen Receptor Pathway Inhibitors in Metastatic Castration-Resistant Prostate Cancer
    Kostos, Louise
    Tran, Ben
    Azad, Arun A.
    DRUGS, 2024, 84 (09) : 1093 - 1109
  • [7] Emerging cell cycle inhibitors for treating metastatic castration-resistant prostate cancer
    Batra, Anupam
    Winquist, Eric
    EXPERT OPINION ON EMERGING DRUGS, 2018, 23 (04) : 271 - 282
  • [8] PARP inhibitors for metastatic castration-resistant prostate cancer: Biological rationale and current evidence
    Bienkowski, Michal
    Tomasik, Bartlomiej
    Braun, Marcin
    Jassem, Jacek
    CANCER TREATMENT REVIEWS, 2022, 104
  • [9] PARPing up the right tree; an overview of PARP inhibitors for metastatic castration-resistant prostate cancer
    Slootbeek, Peter H. J.
    Overbeek, Joanneke K.
    Ligtenberg, Marjolijn J. L.
    van Erp, Nielka P.
    Mehra, Niven
    CANCER LETTERS, 2023, 577
  • [10] PARP inhibition in castration-resistant prostate cancer
    Nappi, Lucia
    Gleave, Martin E.
    FUTURE ONCOLOGY, 2016, 12 (05) : 577 - 580